Monday, April 29, 2013
Covance, a provider of drug development services, has completed the expansion of its central laboratory facility in Singapore to enhance the company’s current service offerings and position it to meet current and future growth of drug development in the Asia Pacific region. The expansion is the latest in Covance’s continued investment in Singapore, and an important element of the strategic investment plans for the Asia Pacific region that also includes recent growth in operations in China and Japan.
Japan’s first public-private partnership to advance the development of new health technologies for the developing world The Global Health Innovative Technology Fund (GHIT Fund) has officially launched. The GHIT Fund has been established to advance the R&D of new medicines, vaccines and diagnostics to fight infectious diseases in the developing world.
GlaxoSmithKline and A*STAR‘s Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (EBFs) specifically for emerging markets. EBFs are medicines which are reformulated to provide additional patient benefit.
TheraVida, a biopharmaceutical company based in Mountain View, Calif., and South Korea-based SK Chemicals have signed a license agreement for two of TheraVida’s proprietary combination drug product candidates, THVD-201 and THVD-202. The agreement grants SK Chemicals exclusive rights to develop and commercialize THVD-201 and THVD-202 in South Korea for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI).
Executing its mission to bring zero-delay imaging technology to clinical trials around the world, AG Mednet has signed a Master Services Agreement with Biovisiq, a Japanese imaging core laboratory (ICL), with an aim to set the new industry standard for imaging data quality, compliance and efficiency.